Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank McCormick

Showing results (251-260 of 303) with videos related to

Pageof 31
Sort By:
Progress in Transplantation (Aliso Viejo, Calif.)|November 16, 2023
Report From a Multidisciplinary Symposium on the Future of Living Kidney Donor TransplantationThomas G Peters, John J Fung, Janet Radcliffe-Richards, et al.
The Journal of Biological Chemistry|December 15, 2019
Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimerMukul Sherekar, Sae-Won Han, Rodolfo Ghirlando, et al.
The Journal of Biological Chemistry|June 5, 2025
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraintsPatrick Alexander, Albert H Chan, Dana Rabara, et al.
American Journal of Medical Genetics. Part A|January 19, 2010
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiersJoseph L Kissil, Jaishri O Blakeley, Rosalie E Ferner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Chi-Heng Wu, Chen-Yen Yang, et al.
The Journal of Biological Chemistry|January 18, 2024
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by <sup>31</sup>P NMRAlok K Sharma, Jun Pei, Yue Yang, et al.
Plos One|June 5, 2012
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomasKeiko Shoji, Katsutoshi Oda, Tomoko Kashiyama, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 23, 2023
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerizationLucy C Young, Ruby Goldstein de Salazar, Sae-Won Han, et al.
SLAS Discovery : Advancing Life Sciences R & D|April 26, 2021
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 InhibitionLick Pui Lai, Viviane Brel, Kanika Sharma, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Modulation of the 14-3-3σ/C-RAF "auto"inhibited complex by molecular gluesMarkella Konstantinidou, Holly R Vickery, Marloes A M Pennings, et al.
Pageof 31

Showing results (251-260 of 303) with videos related to

Sort By:
Pageof 31
Progress in Transplantation (Aliso Viejo, Calif.)|November 16, 2023
Report From a Multidisciplinary Symposium on the Future of Living Kidney Donor TransplantationThomas G Peters, John J Fung, Janet Radcliffe-Richards, et al.
The Journal of Biological Chemistry|December 15, 2019
Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimerMukul Sherekar, Sae-Won Han, Rodolfo Ghirlando, et al.
The Journal of Biological Chemistry|June 5, 2025
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraintsPatrick Alexander, Albert H Chan, Dana Rabara, et al.
American Journal of Medical Genetics. Part A|January 19, 2010
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiersJoseph L Kissil, Jaishri O Blakeley, Rosalie E Ferner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Chi-Heng Wu, Chen-Yen Yang, et al.
The Journal of Biological Chemistry|January 18, 2024
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by <sup>31</sup>P NMRAlok K Sharma, Jun Pei, Yue Yang, et al.
Plos One|June 5, 2012
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomasKeiko Shoji, Katsutoshi Oda, Tomoko Kashiyama, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 23, 2023
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerizationLucy C Young, Ruby Goldstein de Salazar, Sae-Won Han, et al.
SLAS Discovery : Advancing Life Sciences R & D|April 26, 2021
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 InhibitionLick Pui Lai, Viviane Brel, Kanika Sharma, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
Modulation of the 14-3-3σ/C-RAF "auto"inhibited complex by molecular gluesMarkella Konstantinidou, Holly R Vickery, Marloes A M Pennings, et al.
Pageof 31